Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021
<strong<Foundation</strong<: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which is part of the protocol used in the country. <br /<<strong<Objective</strong<: to determine the Jusvinza therapeutic resolution in confirmed COVID-19 patients. <br /<<strong<Methods</strong<: a descriptive study carried out from January to September 2021, at the Dr. Joaquín Castillo Duany Military Hospital, in Santiago de Cuba. The universe consisted of 166 confirmed COVID-19 cases, to whom Jusvinza was administered. Some clinical variables (clinical status, associated non-communicable diseases, clinical progression), epidemiological (age, sex) and pharmacological (resolving, duration in days) were analyzed. A data extraction form was used, which was taken from the medical records. <br /<<strong<Results</strong<: morbidity and mortality from COVID-19 was higher in males, related to comorbidities and age over 60 years; The female sex was the one with the greatest response to treatment with Jusvinza (71.7%), which increased its percentage in the absence of associated chronic non-communicable diseases (81.4%). High-risk patients had the lowest mortality (15.8%). <br /<<strong<Conclusions</strong<: resolution in confirmed COVID-19 patients treated with Jusvinza was higher in high-risk cases than in severe and critical cases..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Medisur - 22(2024), 1, Seite 120-126 |
| Sprache: |
Spanisch |
|---|
| Beteiligte Personen: |
Sandra Caridad Laurencio Vallina [VerfasserIn] |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
Factores inmunitarios |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ095568689 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ095568689 | ||
| 003 | DE-627 | ||
| 005 | 20240413112936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||spa c | ||
| 035 | |a (DE-627)DOAJ095568689 | ||
| 035 | |a (DE-599)DOAJf93995219a6041a2a9193939f3c95718 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 050 | 0 | |a R5-920 | |
| 050 | 0 | |a RA1-1270 | |
| 100 | 0 | |a Sandra Caridad Laurencio Vallina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a <strong<Foundation</strong<: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which is part of the protocol used in the country. <br /<<strong<Objective</strong<: to determine the Jusvinza therapeutic resolution in confirmed COVID-19 patients. <br /<<strong<Methods</strong<: a descriptive study carried out from January to September 2021, at the Dr. Joaquín Castillo Duany Military Hospital, in Santiago de Cuba. The universe consisted of 166 confirmed COVID-19 cases, to whom Jusvinza was administered. Some clinical variables (clinical status, associated non-communicable diseases, clinical progression), epidemiological (age, sex) and pharmacological (resolving, duration in days) were analyzed. A data extraction form was used, which was taken from the medical records. <br /<<strong<Results</strong<: morbidity and mortality from COVID-19 was higher in males, related to comorbidities and age over 60 years; The female sex was the one with the greatest response to treatment with Jusvinza (71.7%), which increased its percentage in the absence of associated chronic non-communicable diseases (81.4%). High-risk patients had the lowest mortality (15.8%). <br /<<strong<Conclusions</strong<: resolution in confirmed COVID-19 patients treated with Jusvinza was higher in high-risk cases than in severe and critical cases. | ||
| 650 | 4 | |a infecciones por coronavirus | |
| 650 | 4 | |a factores inmunitarios | |
| 650 | 4 | |a morbilidad | |
| 650 | 4 | |a mortalidad | |
| 650 | 4 | |a resultado del tratamiento | |
| 653 | 0 | |a Medicine (General) | |
| 653 | 0 | |a Public aspects of medicine | |
| 700 | 0 | |a Martha María Arias Carbonell |e verfasserin |4 aut | |
| 700 | 0 | |a Leonardo Ramos Hechavarría |e verfasserin |4 aut | |
| 700 | 0 | |a Dayami Lescay Balanquet |e verfasserin |4 aut | |
| 700 | 0 | |a Roger Pina Núñez |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Medisur |d Centro Provincial de Información de Ciencias Médicas. Cienfuegos, 2018 |g 22(2024), 1, Seite 120-126 |w (DE-627)DOAJ000121347 |x 1727897X |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g pages:120-126 |
| 856 | 4 | 0 | |u https://doaj.org/article/f93995219a6041a2a9193939f3c95718 |z kostenfrei |
| 856 | 4 | 0 | |u http://medisur.sld.cu/index.php/medisur/article/view/45089 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1727-897X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1 |h 120-126 | ||